glp-1 medical prescriptions lubbock A new clinical trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Top Clinical Trials near Knoxville,

Phase 2 results at 48 weeks (Jastreboff et al., NEJM 2023): Phase 3 TRIUMPH-4 at 68 weeks (Lilly Press Release, Dec 2025): The 12 mg dose produced 28.7% body weight loss, an average of 71.2 lbs from a 248.5 lb baseline

limited employer exceptions with PA Blue Cross Blue Shield Major 2026 coverage restrictions announced Cigna Often covers with step therapy requirements UnitedHealthcare Coverage varies by plan

Metabolic Health Improvements : Positive changes in blood sugar, blood pressure, and cholesterol levels have been observed, contributing to better health outcomes

But its smells can also give clues on what's happening inside our bodies